{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:39:44Z","timestamp":1792089584504,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014869","name":"Army Medical University Xinqiao Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104453"],"award-info":[{"award-number":["82104453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012397","name":"Army Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.neo.2024.100966","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T22:09:18Z","timestamp":1705529358000},"page":"100966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma"],"prefix":"10.1016","volume":"48","author":[{"given":"Qiaoling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changpeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2024.100966_bib0001","article-title":"RAI14 promotes melanoma progression by regulating the FBXO32\/c-MYC pathway","volume":"23","author":"Xu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2024.100966_bib0002","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.neo.2024.100966_bib0003","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.neo.2024.100966_bib0004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01525316","article-title":"Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide","volume":"39","author":"Salgaller","year":"1994","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.neo.2024.100966_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.100966_bib0006","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study","volume":"36","author":"Callahan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.100966_bib0007","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2024.100966_bib0008","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2024.100966_bib0009","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neo.2024.100966_bib0010","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1158\/1078-0432.CCR-06-1405","article-title":"Aurora kinases: new targets for cancer therapy","volume":"12","author":"Carvajal","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2024.100966_bib0011","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s12276-022-00750-y","article-title":"Mitotic protein kinase-driven crosstalk of machineries for mitosis and metastasis","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.neo.2024.100966_bib0012","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2024.100966_bib0013","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10753-014-9990-2","article-title":"Aurora kinase a regulates m1 macrophage polarization and plays a role in experimental autoimmune encephalomyelitis","volume":"38","author":"Ding","year":"2015","journal-title":"Inflammation"},{"key":"10.1016\/j.neo.2024.100966_bib0014","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.37986","article-title":"Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models","volume":"65","author":"Glant","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.neo.2024.100966_bib0015","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1021\/acs.jproteome.5b00645","article-title":"Phosphoproteomic analysis of aurora kinase inhibition in monopolar cytokinesis","volume":"14","author":"Polat","year":"2015","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.neo.2024.100966_bib0016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neo.2024.100966_bib0017","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrd.2018.148","article-title":"Regulatory T cells in the treatment of disease","volume":"17","author":"Sharabi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2024.100966_bib0018","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.neo.2024.100966_bib0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fonc.2018.00450","article-title":"Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data","volume":"8","author":"Giulietti","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2024.100966_bib0020","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1038\/s41467-021-26299-4","article-title":"Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma","volume":"12","author":"Du","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2024.100966_bib0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12013-022-01124-x","article-title":"Ferroptosis-related NFE2L2 and NOX4 genes are potential risk prognostic biomarkers and correlated with immunogenic features in glioma","volume":"81","author":"Lin","year":"2023","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.neo.2024.100966_bib0022","first-page":"3070","article-title":"G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer","volume":"11","author":"Oshi","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.neo.2024.100966_bib0023","first-page":"189","article-title":"The phenotypic characterization of naturally occurring regulatory CD4+CD25+ T cells","volume":"3","author":"Yi","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.neo.2024.100966_bib0024","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","article-title":"B cell regulation in cancer and anti-tumor immunity","volume":"14","author":"Sarvaria","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.neo.2024.100966_bib0025","doi-asserted-by":"crossref","first-page":"14649","DOI":"10.1038\/ncomms14649","article-title":"Suppressive IL-17A(+)Foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) T(reg) cells are a source of tumour-associated T(reg) cells","volume":"8","author":"Downs-Canner","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2024.100966_bib0026","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2024.100966_bib0027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.molimm.2016.02.002","article-title":"Signaling via the CytoR\/JAK\/STAT\/SOCS pathway: emergence during evolution","volume":"71","author":"Liongue","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.neo.2024.100966_bib0028","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2024.100966_bib0029","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neo.2024.100966_bib0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7150\/ijbs.7.651","article-title":"Dual roles of immune cells and their factors in cancer development and progression","volume":"7","author":"Zamarron","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.neo.2024.100966_bib0031","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2014.14","article-title":"The aurora kinases in cell cycle and leukemia","volume":"34","author":"Goldenson","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2024.100966_bib0032","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.leukres.2011.04.008","article-title":"A phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia","volume":"35","author":"Tsuboi","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.neo.2024.100966_bib0033","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/leu.2012.186","article-title":"MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2024.100966_bib0034","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1464-410X.2012.11404.x","article-title":"Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure","volume":"111","author":"Meulenbeld","year":"2013","journal-title":"BJU Int."},{"key":"10.1016\/j.neo.2024.100966_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2012.07.020","article-title":"ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer","volume":"49","author":"Matulonis","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2024.100966_bib0036","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00262-020-02748-9","article-title":"Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity","volume":"70","author":"Punt","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.neo.2024.100966_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","article-title":"Targeting AURKA in cancer: molecular mechanisms and opportunities for Cancer therapy","volume":"20","author":"Du","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2024.100966_bib0038","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1541-7786.MCR-19-1226","article-title":"Inhibition of aurora-A promotes CD8(+) T-cell infiltration by mediating IL10 production in cancer cells","volume":"18","author":"Han","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.neo.2024.100966_bib0039","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-18-3397","article-title":"Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer","volume":"79","author":"Yin","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2024.100966_bib0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2024.100966_bib0041","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12253-016-0138-6","article-title":"Macrophage migration inhibitory factor (MIF): biological activities and relation with cancer","volume":"23","author":"Nobre","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.neo.2024.100966_bib0042","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/2045893217724141","article-title":"Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension","volume":"7","author":"Marshall","year":"2017","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.neo.2024.100966_bib0043","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/2326-6066.CIR-15-0070-T","article-title":"MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation","volume":"4","author":"Yaddanapudi","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.neo.2024.100966_bib0044","doi-asserted-by":"crossref","unstructured":"H. Huai, J. Li, J. Li, H. Lan, Transcriptome analysis and single-cell sequencing analysis constructed the metastasis-related signature in melanoma and identifi ed CD74 as a novel biomarker (2023).","DOI":"10.21203\/rs.3.rs-2718299\/v1"},{"key":"10.1016\/j.neo.2024.100966_bib0045","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fimmu.2018.01132","article-title":"Blockade of MIF-CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma","volume":"9","author":"Figueiredo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2024.100966_bib0046","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846915","article-title":"MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma","volume":"9","author":"de Azevedo","year":"2020","journal-title":"Oncoimmunology"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:13:39Z","timestamp":1761484419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":46,"alternative-id":["S1476558624000034"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.100966","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.100966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100966"}}